Allergy assessment of foods or ingredients derived from biotechnology, gene-modified organisms, or novel foods.
The introduction of novel proteins into foods carries a risk of eliciting allergic reactions in individuals sensitive to the introduced protein and a risk of sensitizing susceptible individuals. No single predictive test exists to perform a hazard assessment in relation to allergenic properties of newly expressed proteins in gene-modified organisms (GMOs). Instead, performance of a weighted risk analysis based on the decision tree approach has been suggested. The individual steps of this analysis comprise sequence homology to known allergens, specific or targeted serum screens for immunoglobulin E (IgE) cross-reactions to known allergens, digestability studies of the proteins in simulated gastric and/or intestinal fluids, and animal studies. These steps are discussed and five examples of risk evaluation of GMOs or novel foods are presented. These include ice-structuring protein derived from fish, microbial transglutaminase, GMO-soybeans, amylase and the Nangai nut.
Poulsen
Lars K
LK
Laboratory of Medical Allergology, Allergy Clinic, National University Hospital, Copenhagen, Denmark. lkpallgy@inet.uni2.dk
D000485:Allergens / Q000009:adverse effects* / Q000737:chemistry / Q000235:genetics / Q000302:isolation & purification; D000818:Animals; D001709:Biotechnology; D003663:Decision Trees; D005512:Food Hypersensitivity / Q000517:prevention & control; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology*; D023421:Models, Animal; D030781:Organisms, Genetically Modified; D011506:Proteins / Q000009:adverse effects* / Q000737:chemistry / Q000235:genetics; D012449:Safety; D017386:Sequence Homology, Amino Acid
D000485:Allergens; D011506:Proteins; D007073:Immunoglobulin E